secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001439222-22-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q3 2022: PYRUKYND revenue $3.5M, 56 patients on therapy; CHMP positive opinion received
--------------------------------------------------------------------------------

- PYRUKYND net revenue $3.5M in Q3 2022; 56 patients on therapy (+51% Q/Q), 84 patients enrolled (+64%).
- Received positive CHMP opinion for PYRUKYND in adult PK deficiency; filed with UK MHRA.
- Cash $1.0B as of Sept 30; subsequently received $131.8M from sale of TIBSOVO royalty rights.
- Net loss from continuing ops $81.7M vs $84.3M in Q3 2021; R&D $65.0M, SG&A $29.1M.
- Appointed Cecilia Jones as CFO; Rahul Ballal and Cynthia Smith to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/0001439222-22-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/agio-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001439222-22-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer